In addition to targeted therapies (TT), the use of immune checkpoint blockade (ICB) against programmed cell death‐1 (PD‐1) protein or cytotoxic T lymphocyte antigen‐4 (CTLA‐4) has also greatly improved the treatment of advanced melanoma, with notable efficacy and long‐term survival benefits.13, 14, 15, 16. The gene discussed is CTLA4; the disease is melanoma.